Cumberland Pharmaceuticals (CPIX) Non-Current Assets (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) posted Non-Current Assets of $38.2 million for Q1 2026, down 3.92% sequentially from $39.8 million in Q4 2025, and little changed YoY from $38.1 million in Q1 2025.
Cumberland Pharmaceuticals (CPIX) Non-Current Assets (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has reported Non-Current Assets for 17 years, with the latest figure at $38.2 million in Q1 2026.
- Quarterly Non-Current Assets changed 0.39% year-over-year to $38.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $150.6 million (down 6.81% YoY) and the FY2025 annual result came in at $39.8 million, up 1.62% from the prior year.
- Non-Current Assets eased to $38.2 million in Q1 2026 per CPIX's latest filing, from $39.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $51.4 million in Q1 2022 and troughed at $36.0 million in Q3 2025.
- A 5-year average of $42.9 million and a median of $42.9 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets rose 21.36% in 2022, then dropped 15.99% in 2025.
- Over 5 years, Non-Current Assets stood at $47.1 million in 2022, then declined by 2.11% to $46.1 million in 2023, then dropped by 15.05% to $39.1 million in 2024, then rose by 1.62% to $39.8 million in 2025, then retreated by 3.92% to $38.2 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $38.2 million, $39.8 million, and $36.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Cumberland Pharmaceuticals | 114.68 Mn | 110.82 Mn | - | 29.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.24 Mn |
| Mar 31, 2026 | 38.21 Mn |
| Dec 31, 2025 | 39.76 Mn |
| Sep 30, 2025 | 35.96 Mn |
| Jun 30, 2025 | 36.70 Mn |
| Mar 31, 2025 | 38.06 Mn |
| Dec 31, 2024 | 39.13 Mn |
| Sep 30, 2024 | 41.51 Mn |
| Jun 30, 2024 | 42.94 Mn |
| Mar 31, 2024 | 45.30 Mn |
| Dec 31, 2023 | 46.06 Mn |
| Sep 30, 2023 | 45.98 Mn |
| Jun 30, 2023 | 45.70 Mn |
| Mar 31, 2023 | 45.66 Mn |
| Dec 31, 2022 | 47.05 Mn |
| Sep 30, 2022 | 41.62 Mn |
| Jun 30, 2022 | 48.77 Mn |
| Mar 31, 2022 | 51.36 Mn |
| Dec 31, 2021 | 38.77 Mn |
| Sep 30, 2021 | 40.36 Mn |